Hepcidin and Iron in Health and Disease

Literature Cited

1. 1.

   Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. 2021. Iron deficiency. Lancet 397:233–48
   [Google Scholar]
2. 2.

   Pantopoulos K. 2018. Inherited disorders of iron overload. Front. Nutr. 5:103
   [Google Scholar]
3. 3.

   Park CH, Valore EV, Waring AJ, Ganz T. 2001. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 276:7806–10
   [Google Scholar]
4. 4.

   Sangkhae V, Nemeth E. 2017. Regulation of the iron homeostatic hormone hepcidin. Adv. Nutr. 8:126–36
   [Google Scholar]
5. 5.

   Ganz T, Nemeth E. 2011. Hepcidin and disorders of iron metabolism. Annu. Rev. Med. 62:347–60
   [Google Scholar]
6. 6.

   Kautz L, Jung G, Valore EV et al. 2014. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 46:678–84
   [Google Scholar]
7. 7.

   Sangkhae V, Fisher AL, Chua KJ et al. 2020. Maternal hepcidin determines embryo iron homeostasis in mice. Blood 136:2206–16
   [Google Scholar]
8. 8.

   Nemeth E, Rivera S, Gabayan V et al. 2004. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig. 113:1271–76
   [Google Scholar]
9. 9.

   Stefanova D, Raychev A, Arezes J et al. 2017. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. Blood 130:245–57
   [Google Scholar]
10. 10.

    Lakhal-Littleton S, Wolna M, Chung YJ et al. 2016. An essential cell-autonomous role for hepcidin in cardiac iron homeostasis. eLife 5:e19804
    [Google Scholar]
11. 11.

    Malerba M, Louis S, Cuvellier S et al. 2020. Epidermal hepcidin is required for neutrophil response to bacterial infection. J. Clin. Investig. 130:329–34
    [Google Scholar]
12. 12.

    Bessman NJ, Mathieu JRR, Renassia C et al. 2020. Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing. Science 368:186–89
    [Google Scholar]
13. 13.

    Donovan A, Lima CA, Pinkus JL et al. 2005. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 1:191–200
    [Google Scholar]
14. 14.

    Taniguchi R, Kato HE, Font J et al. 2015. Outward- and inward-facing structures of a putative bacterial transition-metal transporter with homology to ferroportin. Nat. Commun. 6:8545
    [Google Scholar]
15. 15.

    Zhang DL, Ghosh MC, Ollivierre H et al. 2018. Ferroportin deficiency in erythroid cells causes serum iron deficiency and promotes hemolysis due to oxidative stress. Blood 132:2078–87
    [Google Scholar]
16. 16.

    Aschemeyer S, Qiao B, Stefanova D et al. 2018. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood 131:899–910
    [Google Scholar]
17. 17.

    Qiao B, Sugianto P, Fung E et al. 2012. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab 15:918–24
    [Google Scholar]
18. 18.

    Nemeth E, Tuttle MS, Powelson J et al. 2004. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–93
    [Google Scholar]
19. 19.

    Billesbolle CB, Azumaya CM, Kretsch RC et al. 2020. Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms. Nature 586:807–11
    [Google Scholar]
20. 20.

    Preza GC, Ruchala P, Pinon R et al. 2011. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J. Clin. Investig. 121:4880–88
    [Google Scholar]
21. 21.

    Schwartz AJ, Das NK, Ramakrishnan SK et al. 2019. Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload. J. Clin. Investig. 129:336–48
    [Google Scholar]
22. 22.

    Fisher AL, Babitt JL. 2022. Coordination of iron homeostasis by bone morphogenetic proteins: current understanding and unanswered questions. Dev. Dyn. 251:26–46
    [Google Scholar]
23. 23.

    Silvestri L, Nai A, Dulja A, Pagani A. 2019. Hepcidin and the BMP-SMAD pathway: an unexpected liaison. Vitam. Horm. 110:71–99
    [Google Scholar]
24. 24.

    Canali S, Zumbrennen-Bullough KB, Core AB et al. 2017. Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. Blood 129:405–14
    [Google Scholar]
25. 25.

    Canali S, Wang CY, Zumbrennen-Bullough KB et al. 2017. Bone morphogenetic protein 2 controls iron homeostasis in mice independent of Bmp6. Am. J. Hematol. 92:1204–13
    [Google Scholar]
26. 26.

    Kautz L, Meynard D, Monnier A et al. 2008. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 112:1503–9
    [Google Scholar]
27. 27.

    Kautz L, Jung G, Du X et al. 2015. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia. Blood 126:2031–37
    [Google Scholar]
28. 28.

    Wang CY, Xu Y, Traeger L et al. 2020. Erythroferrone lowers hepcidin by sequestering BMP2/6 heterodimer from binding to the BMP type I receptor ALK3. Blood 135:453–56
    [Google Scholar]
29. 29.

    Artuso I, Pettinato M, Nai A et al. 2019. Transient decrease of serum iron after acute erythropoietin treatment contributes to hepcidin inhibition by ERFE in mice. Haematologica 104:e87–90
    [Google Scholar]
30. 30.

    Gonzalez-Fernandez D, Nemeth E, Pons EDC et al. 2021. INTERGROWTH-21 identifies high prevalence of low symphysis-fundal height in indigenous pregnant women experiencing multiple infections, nutrient deficiencies, and inflammation: the Maternal Infections, Nutrient Deficiencies, and Inflammation (MINDI) cohort. Curr. Dev. Nutr. 5:nzab012
    [Google Scholar]
31. 31.

    Armitage AE, Eddowes LA, Gileadi U et al. 2011. Hepcidin regulation by innate immune and infectious stimuli. Blood 118:4129–39
    [Google Scholar]
32. 32.

    Kim A, Fung E, Parikh SG et al. 2014. A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood 123:1129–36
    [Google Scholar]
33. 33.

    Ganz T. 2019. Anemia of inflammation. N. Engl. J. Med. 381:1148–57
    [Google Scholar]
34. 34.

    Peters HP, Laarakkers CM, Pickkers P et al. 2013. Tubular reabsorption and local production of urine hepcidin-25. BMC Nephrol 14:70
    [Google Scholar]
35. 35.

    Zaritsky J, Young B, Gales B et al. 2010. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin. J. Am. Soc. Nephrol. 5:1010–14
    [Google Scholar]
36. 36.

    Anderson GJ, Bardou-Jacquet E. 2021. Revisiting hemochromatosis: genetic versus phenotypic manifestations. Ann. Transl. Med. 9:731
    [Google Scholar]
37. 37.

    Knutson MD. 2019. Non-transferrin-bound iron transporters. Free Radic. Biol. Med. 133:101–11
    [Google Scholar]
38. 38.

    Cooray SD, Heerasing NM, Selkrig LA et al. 2018. Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report. J. Med. Case Rep. 12:18
    [Google Scholar]
39. 39.

    Girelli D, Trombini P, Busti F et al. 2011. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 96:500–6
    [Google Scholar]
40. 40.

    Girelli D, Busti F, Brissot P et al. 2022. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood 139:3018–29
    [Google Scholar]
41. 41.

    Taher AT, Musallam KM, Cappellini MD. 2021. β-Thalassemias. N. Engl. J. Med. 384:727–43
    [Google Scholar]
42. 42.

    Ganz T, Jung G, Naeim A et al. 2017. Immunoassay for human serum erythroferrone. Blood 130:1243–46
    [Google Scholar]
43. 43.

    Pasricha SR, Frazer DM, Bowden DK, Anderson GJ. 2013. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood 122:124–33
    [Google Scholar]
44. 44.

    Origa R, Galanello R, Ganz T et al. 2007. Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica 92:583–88
    [Google Scholar]
45. 45.

    Finberg KE, Heeney MM, Campagna DR et al. 2008. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat. Genet. 40:569–71
    [Google Scholar]
46. 46.

    Heeney MM, Guo D, De Falco L et al. 2018. Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency. Blood 132:448–52
    [Google Scholar]
47. 47.

    Silvestri L, Pagani A, Nai A et al. 2008. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 8:502–11
    [Google Scholar]
48. 48.

    Enns CA, Jue S, Zhang AS. 2020. The ectodomain of matriptase-2 plays an important nonproteolytic role in suppressing hepcidin expression in mice. Blood 136:989–1001
    [Google Scholar]
49. 49.

    Weiss G, Ganz T, Goodnough LT. 2019. Anemia of inflammation. Blood 133:40–50
    [Google Scholar]
50. 50.

    Weir MR. 2021. Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents. Am. J. Nephrol. 52:450–66
    [Google Scholar]
51. 51.

    Babitt JL, Eisenga MF, Haase VH et al. 2021. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) conference. Kidney Int. 99:1280–95
    [Google Scholar]
52. 52.

    Pergola PE, Devalaraja M, Fishbane S et al. 2021. Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J. Am. Soc. Nephrol. 32:211–22
    [Google Scholar]
53. 53.

    Madeddu C, Gramignano G, Astara G et al. 2018. Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach. Front. Physiol. 9:1294
    [Google Scholar]
54. 54.

    Maes K, Nemeth E, Roodman GD et al. 2010. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 116:3635–44
    [Google Scholar]
55. 55.

    Hara M, Ando M, Tsuchiya K, Nitta K. 2015. Serum hepcidin-25 level linked with high mortality in patients with non-Hodgkin lymphoma. Ann. Hematol. 94:603–8
    [Google Scholar]
56. 56.

    Oh ST, Talpaz M, Gerds AT et al. 2020. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 4:4282–91
    [Google Scholar]
57. 57.

    Pietrangelo A. 2017. Ferroportin disease: pathogenesis, diagnosis and treatment. Haematologica 102:1972–84
    [Google Scholar]
58. 58.

    Diepeveen LE, Laarakkers CMM, Martos G et al. 2019. Provisional standardization of hepcidin assays: creating a traceability chain with a primary reference material, candidate reference method and a commutable secondary reference material. Clin. Chem. Lab. Med. 57:864–72
    [Google Scholar]
59. 59.

    Schaap CC, Hendriks JC, Kortman GA et al. 2013. Diurnal rhythm rather than dietary iron mediates daily hepcidin variations. Clin. Chem. 59:527–35
    [Google Scholar]
60. 60.

    Ganz T, Olbina G, Girelli D et al. 2008. Immunoassay for human serum hepcidin. Blood 112:4292–97
    [Google Scholar]
61. 61.

    Beutler B, Jiang Z, Georgel P et al. 2006. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol. 24:353–89
    [Google Scholar]
62. 62.

    Zaritsky J, Young B, Wang HJ et al. 2009. Hepcidin—a potential novel biomarker for iron status in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4:1051–56
    [Google Scholar]
63. 63.

    Theurl I, Aigner E, Theurl M et al. 2009. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 113:5277–86
    [Google Scholar]
64. 64.

    Bregman DB, Morris D, Koch TA et al. 2013. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am. J. Hematol. 88:97–101
    [Google Scholar]
65. 65.

    Martensson J, Glassford NJ, Jones S et al. 2015. Urinary neutrophil gelatinase-associated lipocalin to hepcidin ratio as a biomarker of acute kidney injury in intensive care unit patients. Minerva Anestesiol 81:1192–200
    [Google Scholar]
66. 66.

    Prowle JR, Calzavacca P, Licari E et al. 2015. Combination of biomarkers for diagnosis of acute kidney injury after cardiopulmonary bypass. Ren. Fail. 37:408–16
    [Google Scholar]
67. 67.

    Albert C, Haase M, Albert A et al. 2021. Predictive value of plasma NGAL:hepcidin-25 for major adverse kidney events after cardiac surgery with cardiopulmonary bypass: a pilot study. Ann. Lab. Med. 41:357–65
    [Google Scholar]
68. 68.

    Leaf DE, Rajapurkar M, Lele SS et al. 2019. Iron, hepcidin, and death in human AKI. J. Am. Soc. Nephrol. 30:493–504
    [Google Scholar]
69. 69.

    Lasocki S, Lefebvre T, Mayeur C et al. 2018. Iron deficiency diagnosed using hepcidin on critical care discharge is an independent risk factor for death and poor quality of life at one year: an observational prospective study on 1161 patients. Crit. Care 22:314
    [Google Scholar]
70. 70.

    Jiang Y, Jiang FQ, Kong F et al. 2019. Inflammatory anemia-associated parameters are related to 28-day mortality in patients with sepsis admitted to the ICU: a preliminary observational study. Ann. Intensive Care 9:67
    [Google Scholar]
71. 71.

    Girelli D, Nemeth E, Swinkels DW. 2016. Hepcidin in the diagnosis of iron disorders. Blood 127:2809–13
    [Google Scholar]
72. 72.

    Casu C, Oikonomidou PR, Chen H et al. 2016. Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera. Blood 128:265–76
    [Google Scholar]
73. 73.

    Schmidt PJ, Toudjarska I, Sendamarai AK et al. 2013. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe^−/− mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Blood 121:1200–8
    [Google Scholar]
74. 74.

    Guo S, Casu C, Gardenghi S et al. 2013. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J. Clin. Investig. 123:1531–41
    [Google Scholar]
75. 75.

    Ginzburg Y, Kirubamoorthy K, Salleh S et al. 2021. Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy. Blood 138(Suppl. 1):390
    [Google Scholar]
76. 76.

    Richard F, van Lier JJ, Roubert B et al. 2020. Oral ferroportin inhibitor VIT-2763: first-in-human, phase 1 study in healthy volunteers. Am. J. Hematol. 95:68–77
    [Google Scholar]
77. 77.

    Altamura S, Schaeper U, Dames S et al. 2019. SLN124, a GalNAc-siRNA conjugate targeting TMPRSS6, efficiently prevents iron overload in hereditary haemochromatosis type 1. Hemasphere 3:e301
    [Google Scholar]
78. 78.

    Katsarou A, Pantopoulos K 2018. Hepcidin therapeutics. Pharmaceuticals 11:127
    [Google Scholar]
79. 79.

    Hawula ZJ, Wallace DF, Subramaniam VN, Rishi G. 2019. Therapeutic advances in regulating the hepcidin/ferroportin axis. Pharmaceuticals 12:170
    [Google Scholar]
80. 80.

    Kurzrock R, Voorhees PM, Casper C et al. 2013. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin. Cancer Res. 19:3659–70
    [Google Scholar]
81. 81.

    Kautz L, Jung G, Nemeth E, Ganz T. 2014. Erythroferrone contributes to recovery from anemia of inflammation. Blood 124:2569–74
    [Google Scholar]
82. 82.

    Theurl I, Schroll A, Sonnweber T et al. 2011. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 118:4977–84
    [Google Scholar]
83. 83.

    Kovac S, Boser P, Cui Y et al. 2016. Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels. Haematologica 101:e173–76
    [Google Scholar]
84. 84.

    Vadhan-Raj S, Abonour R, Goldman JW et al. 2017. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J. Hematol. Oncol. 10:73
    [Google Scholar]
85. 85.

    Cooke KS, Hinkle B, Salimi-Moosavi H et al. 2013. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 122:3054–61
    [Google Scholar]
86. 86.

    Sheetz M, Barrington P, Callies S et al. 2019. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br. J. Clin. Pharmacol. 85:935–48
    [Google Scholar]